tiprankstipranks
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Holding CPRX?
Track your performance easily

Catalyst Pharma (CPRX) Ownership - Who Owns Catalyst Pharma?

2,108 Followers

Catalyst Pharma (CPRX) Ownership Overview

5.98%17.90%18.93%26.74%30.46%
18.93% Other Institutional Investors
26.74% ETFs
30.46% Public Companies and Individual Investors
The ownership structure of Catalyst Pharma (CPRX) stock is a mix of institutional, retail, and individual investors. Approximately 63.56% of the company’s stock is owned by Institutional Investors, 5.98% is owned by Insiders, and 30.46% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 23, 2024
xxxxxxxxxxxxx
$301350
Aug 22, 2024
Steve Miller
Chief Op. & Scientific Officer
xxxxxxxxxxxxx
$3052500
Aug 13, 2024
Gary Ingenito
Chief Med. & Reg. Officer
xxxxxxxxxxxxx
$1804000
Aug 13, 2024
xxxxxxxxxxxxx
$664310

Recent Hedge Fund Trading Activity

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
13,232,653Institution11.09%279,870,611
6,816,710Institution5.72%144,173,417
6,229,634Institution5.22%131,756,759
5,273,857Institution4.42%111,542,076
4,478,169Insider3.75%94,713,274
3,113,300Institution2.61%65,846,295
2,750,076Institution2.31%58,164,107
2,203,127Institution1.85%46,596,136
2,021,105Institution1.69%42,746,371
1,730,869Institution1.45%36,607,879

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
5,273,857Institution4.42%111,542,076
1,730,869Institution1.45%36,607,879
1,297,851Institution1.09%27,449,549
1,205,271Institution1.01%25,491,482
1,184,753Institution0.99%25,057,526
963,196Institution0.81%20,371,595
898,657Institution0.75%19,006,596
862,435Institution0.72%18,240,500
742,200Institution0.62%15,697,530
624,820Institution0.52%13,214,943

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
7,172,662Institution6.01%151,701,801
3,532,746Institution2.96%77,013,863
3,044,419Institution2.55%64,389,462
2,739,907Institution2.30%58,606,611
1,948,200Institution1.63%41,204,430
1,663,762Institution1.39%36,270,012
1,323,651Institution1.11%28,312,895
1,079,841Institution0.91%22,838,637
1,009,337Institution0.85%21,589,718
1,003,806Institution0.84%21,230,497

FAQ

Who Owns Catalyst Pharma (CPRX)?
According to the latest TipRanks data, approximately 18.93% of the company's stock is held by institutional investors, 5.98% is held by insiders, and 30.46% is held by retail investors.
    What percentage of Catalyst Pharma (CPRX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 18.93% of Catalyst Pharma (CPRX) stock is held by institutional investors.
      What percentage of Catalyst Pharma (CPRX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 30.46% of Catalyst Pharma (CPRX) stock is held by retail investors.
        Who owns the most shares of Catalyst Pharma (CPRX)?
        iShares owns the most shares of Catalyst Pharma (CPRX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis